Comparative Analysis of Biopharmaceutical Companies on NASDAQ

Group 1: Reviva Pharmaceuticals Holdings, Inc. (RVPH) - RVPH is a clinical-stage biopharmaceutical company focused on therapies for central nervous system, respiratory, and metabolic diseases [1] - The current trading price is $0.44, with a target price of $0.39, indicating a potential downside of approximately -11.09% [1] - The significant gap between the current and target price suggests a pessimistic outlook from investment analysts, leading to its exclusion from coverage [1] Group 2: PDS Biotechnology Corporation (PDSB) - PDSB is trading at $0.93, with a discounted cash flow (DCF) valuation of $0.54, resulting in a price percentage difference of -41.72% [2] - The market cap of PDSB is $43.63 million, and it has an earnings per share (EPS) of -0.91, with a negative price-to-earnings (P/E) ratio of -1.58 [2] - This reflects the company's current unprofitability [2] Group 3: IO Biotech, Inc. (IOBT) - IOBT has a current stock price of $1.17 and a DCF valuation of $0.88, leading to a price percentage difference of -24.60% [3] - The market cap of IOBT is $77.08 million, with an EPS of -1.58 and a P/E ratio of -0.63 [3] - This indicates that IOBT is also trading above its intrinsic value, similar to PDSB, but with a slightly better valuation [3] Group 4: Skye Bioscience, Inc. (SKYE) - SKYE has a current stock price of $1.47 and a DCF valuation of $1.86, resulting in a positive price percentage difference of 26.28% [4] - The market cap of SKYE is $45.71 million, with an EPS of -1.06 and a P/E ratio of -3.89 [4] - This suggests that SKYE is undervalued compared to its intrinsic value, indicating potential growth despite current losses [4]